ATAI Life Sciences Acquires Majority Stake in Kures

Eli Lilly Acquires AtaiBeckley

July 17, 2026

Biotechnology

Eli Lilly agreed to acquire all outstanding shares of AtaiBeckley for $6.75 per share in cash, plus contingent value rights worth up to an additional $2.50 per share. The acquisition, valued at approximately $2.8 billion upfront, gives Lilly AtaiBeckley’s clinical-stage neuroplastogen pipeline, including programs for treatment-resistant depression; it was completed on September 11, 2026.

Kuva Labs Acquires Lisata Therapeutics

March 6, 2026

Pharmaceuticals

Kuva Labs, Inc. has entered into a definitive agreement to acquire Lisata Therapeutics, Inc. for $5.00 per share in cash, plus a contingent value right (CVR) that could pay an additional $1.00 per share upon an FDA-related regulatory milestone tied to certepetide. The transaction is expected to close in the second quarter of 2026, subject to customary tender offer conditions, including tender of a majority of Lisata’s outstanding shares.

Asahi Kasei to Acquire Aicuris Anti-infective Cures AG

February 26, 2026

Pharmaceuticals

Asahi Kasei entered into a definitive agreement to acquire Aicuris Anti-infective Cures AG, a German biopharmaceutical company, for approximately €780 million. The acquisition is designed to expand Asahi Kasei’s specialty pharmaceutical platform into severe infectious diseases and to complement its existing transplant and nephrology franchises. A second article reports Asahi Kasei completed the acquisition.

PharmaForceIQ Acquires Aktana

January 9, 2026

Cloud & SaaS

PharmaForceIQ has acquired Aktana in an asset acquisition to integrate Aktana's AI-driven field Next-Best-Action platform into PharmaForceIQ's digital orchestration offering. The deal is intended to create an end-to-end 'optichannel-in-a-box' commercial engagement solution for life sciences, deepen PharmaForceIQ's U.S. footprint and expand reach across LATAM, APAC and EMEA; Canaccord Genuity acted as sole financial advisor.

Petauri Health (Oak Hill) Acquires The Kinetix Group

June 13, 2023

Healthcare Services

Petauri Health, a pharmaceutical commercialization platform formed by Oak Hill Capital, has acquired The Kinetix Group (TKG), a New York–based market access, access marketing, and medical affairs agency. The Kinetix founders will remain in leadership roles as TKG becomes the inaugural add-on to the Petauri platform, expanding the platform's market access, medical affairs, and real-world evidence capabilities.

Atairos Acquires LifeLabs Learning

March 24, 2023

Education

Atairos, an independent strategic investment company, acquired LifeLabs Learning, a provider of manager and team upskilling programs, in a transaction that closed on March 23, 2023. The investment will accelerate LifeLabs Learning’s rollout of digital learning innovations and support growth of its manager-focused training programs; Houlihan Lokey served as exclusive financial advisor to Atairos.